Internet Pioneer In...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$15.12 -0.50 | -3.20%
06/01/12 - 04:00 PM ET
Company Cash Flow
| Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -113.68M | -45.54M | -39.63M | 130.50M |
| Operating Gains/Losses | 0.00 | 841.00K | 94.00K | 3.71M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -14.01M | 2.35M | -728.00K | 13.71M |
| (Increase) Decrease in Inventories | -4.88M | 5.21M | -4.04M | -5.14M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 11.22M | 6.95M | -2.06M | 2.01M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 6.58M | -6.06M | -8.57M | -133.55M |
| Other Non-Cash Items | 33.17M | 21.69M | 17.66M | 13.08M |
| Net Cash From Continuing Operations | -2.48M | -5.91M | -12.25M | 34.59M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -2.48M | -5.91M | -12.25M | 34.59M |
| Sale of Property, Plant & Equipment | 35.00K | 395.00K | 248.00K | 7.72M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -16.99M | -9.40M | -15.79M | -5.50M |
| Acquisitions | -494.77M | 0.00 | -8.00M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 385.51M | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -417.16M | 5.63M | 28.01M | 45.36M |
| Issuance of Debt | 444.10M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 17.19M | 4.74M | 2.59M | 7.06M |
| Repayment of Long-Term Debt | -775.00K | -45.40M | -23.49M | -83.44M |
| Repurchase of Capital Stock | 0.00 | 0.00 | -2.68M | -18.00M |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 4.34M | 0.00 | 246.00K | 80.00K |
| Net Cash From Financing Activities | 464.85M | -40.65M | -23.33M | -94.30M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 45.21M | -40.93M | -7.57M | -14.35M |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
- ContributorBreakout Stocks Of The Week...
- Contributor10 Biotech Stocks Facing FD...
Latest ALKS Headlines from TheStreet
- Cramer's 'Mad Money' Recap: Housing Comeback 05.10.12 | 08:05 pm
- 5 Stocks Insiders Love Right Now 05.02.12 | 11:05 am
- 8 Stocks Rising on Monster Volume 03.28.12 | 12:03 pm
- Insiders Trading TZYM, ALKS, CAKE 03.15.12 | 08:03 am
- The Curse of Amylin's Diabetes Drug Approval 02.06.12 | 08:02 am
- PharMerica, Amylin: After-Hours Trading 01.27.12 | 06:01 pm
- Third Time's The Charm for Approval of Amylin Diabetes Drug 01.27.12 | 03:01 pm
- 7 Stocks Rising on Huge Volume 01.25.12 | 02:01 pm
- UBS: 6 Specialty Pharma Picks to Watch 01.21.12 | 07:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 05.31.12 | 07:05 am
- Alkermes Announces Results From Phase 2 Study Of ALKS 37 For Treatment Of Opioid-Induced Constipation - Business Wire 05.30.12 | 04:05 pm
- Alkermes Presents Positive Clinical Data Of ALKS 5461 At 52nd Annual New Clinical Drug Evaluation Unit Meeting - Business Wire 05.29.12 | 04:05 pm
- Alkermes Plc Completes Secondary Offering Of 24,150,000 Ordinary Shares Held By Elan - Business Wire 03.13.12 | 11:03 am
- Alkermes Plc Prices Secondary Offering Of 21,000,000 Ordinary Shares Held By Elan - Business Wire 03.08.12 | 09:03 am
- Alkermes Plc Announces A Secondary Offering Of 13,900,000 Ordinary Shares Held By Elan - Business Wire 03.07.12 | 04:03 pm
- Alkermes Appoints Mark Stejbach As Chief Commercial Officer - Business Wire 03.05.12 | 07:03 am
- Alkermes’ Corporate Presentation To Be Webcast At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 04:02 pm
- Alkermes Files Resale Shelf Registration In Connection With Elan Shareholder Agreement - Business Wire 02.16.12 | 04:02 pm
- BYDUREONâ¢, First And Only Once-Weekly Type 2 Diabetes Treatment, Now Available In U.S. Pharmacies - PR Newswire 02.13.12 | 08:02 am
Partner Headlines for ALKS
- Healthcare Biz Recap: Teva's Counterfeit Problem, Hopes for Bristol-Myers - Wall St. Cheat Sheet 05.30.12 | 07:05 am
- Alkermes Earnings Call Insights: Adjusted EBITDA, VIVITROL - Wall St. Cheat Sheet 05.29.12 | 01:05 pm
- 9 High-Liquidity Mid Caps Poised For Growth - Seeking Alpha 05.28.12 | 08:05 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- Kinetics Hedge Fund's Top Undervalued Picks - Seeking Alpha 03.23.12 | 05:03 pm
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Alkermes Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan - Benzinga 03.07.12 | 04:03 pm
- Bydureon Physician Survey: Results Yield Insight Into Launch Trajectory - Seeking Alpha 02.22.12 | 08:02 am
- The Zacks Analyst Blog Highlights: Charles Schwab, E*TRADE Financial, TD Ameritrade Holding, Amylin Pharmaceuticals and Alkermes plc - Press Releases - Zacks 02.16.12 | 09:02 am
- Analyzing Friday's Noteworthy Insider Buys And Sells - Seeking Alpha 02.12.12 | 07:02 am
